ProCE Banner Activity

REFINE Cohort 3: Combination Therapy With Navitoclax, a Novel BCL-2 Family Inhibitor, and Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Slideset Download
Conference Coverage

Navitoclax plus ruxolitinib achieved improved SVR35, including in risk groups associated with poor prognosis, along with reductions in bone marrow fibrosis and variant allele frequency of driver gene mutations.

Released: December 15, 2022

Expiration: December 14, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen